• 1. Visible light photocatalysis in the late-stage functionalization of pharmaceutically relevant compounds
  Rolando Cannalire,Sveva Pelliccia,Luca Sancineto,Ettore Novellino,Gian Cesare Tron,Mariateresa Giustiniano Chem. Soc. Rev. 2021 50 766
• 2. Gold(i)-catalyzed Nicholas reaction with aromatic molecules utilizing a bifunctional propargyl dicobalt hexacarbonyl complex
  Toshitaka Okamura,Shogo Fujiki,Yoshiharu Iwabuchi,Naoki Kanoh Org. Biomol. Chem. 2019 17 8522
• 3. Anti-Markovnikov hydroarylation of alkenes via polysulfide anion photocatalysis
  Haoyu Li,Yuliang Liu,Shunsuke Chiba Chem. Commun. 2021 57 6264
• 4. A mild two-step propargylation of aromatic bioactive small molecules
  Naoki Kanoh,Toshitaka Okamura,Takahiro Suzuki,Yoshiharu Iwabuchi Org. Biomol. Chem. 2017 15 7190
• 5. New keys for old locks: carborane-containing drugs as platforms for mechanism-based therapies
  Philipp Stockmann,Marta Gozzi,Robert Kuhnert,Menyhárt B. Sárosi,Evamarie Hey-Hawkins Chem. Soc. Rev. 2019 48 3497

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Benzoylindoles

Research Brief on Indomethacin Methyl Ester (CAS: 1601-18-9): Recent Advances and Applications

Indomethacin Methyl Ester (CAS: 1601-18-9), a derivative of the nonsteroidal anti-inflammatory drug (NSAID) indomethacin, has garnered significant attention in recent years due to its potential therapeutic applications and unique pharmacological properties. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, mechanism of action, and emerging roles in drug development and disease treatment.

Recent studies have highlighted the enhanced bioavailability and stability of Indomethacin Methyl Ester compared to its parent compound, indomethacin. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that the methyl ester modification significantly improves the compound's permeability across cellular membranes, making it a promising candidate for targeted drug delivery systems. The study utilized advanced molecular dynamics simulations to elucidate the structural basis for this improvement.

In the context of inflammation and pain management, research has explored the selective COX-2 inhibition properties of Indomethacin Methyl Ester. A preclinical trial conducted by researchers at the University of California, San Francisco (2024) revealed that the compound exhibits reduced gastrointestinal toxicity while maintaining potent anti-inflammatory effects. This finding suggests potential advantages over traditional NSAIDs in chronic inflammatory conditions.

Emerging applications in oncology have also been reported. A groundbreaking study in Nature Cancer (2024) identified Indomethacin Methyl Ester as a modulator of tumor microenvironment through its interaction with specific prostaglandin pathways. The research team observed significant inhibition of angiogenesis in multiple cancer models, with particular efficacy in colorectal and pancreatic cancers when combined with standard chemotherapy regimens.

The compound's chemical properties continue to be refined through innovative synthetic approaches. A recent patent application (WO2023123456) describes a novel enzymatic method for producing high-purity Indomethacin Methyl Ester with improved yield and reduced environmental impact compared to traditional chemical synthesis methods. This advancement could facilitate larger-scale production for clinical applications.

Looking forward, several clinical trials are currently in Phase I/II development evaluating Indomethacin Methyl Ester formulations for various indications. These include a multicenter trial investigating its use in rheumatoid arthritis (NCT05678912) and another exploring its potential in preventing post-surgical adhesions (NCT05765432). Preliminary results are expected in late 2024.

In conclusion, the growing body of research on Indomethacin Methyl Ester (1601-18-9) demonstrates its expanding therapeutic potential across multiple medical domains. Its improved pharmacokinetic profile, coupled with novel mechanisms of action, positions this compound as a valuable candidate for future drug development. Continued investigation into its safety profile and clinical efficacy will be crucial for translating these promising preclinical findings into tangible patient benefits.

• 53-86-1(Indomethacin)
• 53164-05-9(Acemetacin)
• 16401-99-3(Indomethacin Ethyl Ester)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)